Healius Ltd 2025 AR2
The report highlights Healius' milestone year ended 30 June 2025, marked by the successful sale of Lumus Imaging for $965 million, which enabled the company to repay its existing debt in full and distribute a $300 million special dividend to shareholders. The company transitioned to a single national pathology platform and advanced its T27 strategic plan to improve margins by June 2027. In sustainability, Healius progressed its climate-related disclosures in preparation for mandatory reporting, achieving a 7.6% reduction in total Scope 1 and 2 emissions to 35,759 tCO2-e. Additionally, the company maintained a Net Promoter Score of 80 and continued its community partnerships, including supporting the Children's Cancer Institute.
Company: Healius Ltd
Sector: Health Care
Country: Australia
Year: 2025
Type: AR2
Pages: 116
Back to company
Healius Ltd
Annual Report
The report highlights Healius' milestone year ended 30 June 2025, marked by the successful sale of Lumus Imaging for $965 million, which enabled the company to repay its existing debt in full and distribute a $300 million special dividend to shareholders. The company transitioned to a single national pathology platform and advanced its T27 strategic plan to improve margins by June 2027. In sustainability, Healius progressed its climate-related disclosures in preparation for mandatory reporting, achieving a 7.6% reduction in total Scope 1 and 2 emissions to 35,759 tCO2-e. Additionally, the company maintained a Net Promoter Score of 80 and continued its community partnerships, including supporting the Children's Cancer Institute.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jul 1, 2024 - Jun 30, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Workplace Fatalities
Employees